Researchers determined discontinuing BTK inhibitors appears to be more common than discontinuing venetoclax plus obinutuzumab for older patients with CLL.

Safety and tolerability of different total neoadjuvant therapy strategies in patients with locally advanced rectal cancer. First-in-human, phase 1a, dose escalation study of BGB-B167, a CEA x 4-1BB ...

Cancer treatments, like chemotherapy and radiation, can lead to a potentially fatal condition called tumor lysis syndrome. With this syndrome, the rapid rate of cancer cell death leads to the ...

A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved ...

Secondary malignancies. Tumor lysis syndrome. Radiation sensitization/recall. Avoid extravasation. Hepatic impairment. Children (late cardiovascular dysfunction). Elderly. Embryo-fetal toxicity ...

In clinical trials, the initial tumor lysis is followed by epitope spreading ... MT-401 in an initial trial in relapsed myelodysplastic syndrome and AML patients. Both MT-401 and MT-601 have ...